转移性肾细胞癌全身治疗的序贯与联合策略
伊匹木单抗联合纳武利尤单抗的双免疫检查点阻断在IMDC中危和低危患者中较舒尼替尼提高总生存,VEGFR抑制剂仍是 favorable-risk 患者一线标准。
要点
- 双免疫检查点阻断(伊匹木单抗+纳武利尤单抗)在IMDC中危和低危mRCC患者中较舒尼替尼提高总生存。
- VEGFR抑制剂仍是IMDC favorable-risk患者的一线标准治疗。
- VEGF-TKI联合免疫检查点抑制剂的组合可能在未来提供获益,但需更多数据。
核心结论
- 双免疫检查点阻断(伊匹木单抗联合纳武利尤单抗)在IMDC中危和低危mRCC患者中报告总生存获益,并为部分患者提供持久缓解。
- VEGFR抑制剂仍是favorable-risk患者的一线标准治疗。
- 一线治疗结果决定后续序贯,但最佳序贯尚未确定。
主要发现
- 新型VEGFR酪氨酸激酶抑制剂和多种免疫检查点抑制剂已纳入mRCC当前治疗范式。
- 双检查点阻断联合(伊匹木单抗+纳武利尤单抗)较舒尼替尼在IMDC中危和低危患者中提高总生存。
- VEGF-TKI联合免疫检查点抑制剂可能显示类似稳健获益但安全性特征不同,需更巩固数据。
临床怎么用
- IMDC中危和低危mRCC患者一线可考虑伊匹木单抗联合纳武利尤单抗双免疫检查点阻断。
- IMDC favorable-risk患者一线仍以VEGFR抑制剂为标准治疗。
- 序贯方案应基于一线治疗结果选择,但最佳序贯尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Introduction of additional new agents targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs) has completely modified the systemic treatment of metastatic renal cell carcinoma (mRCC) during the last years. OBJECTIVE: A comprehensive (nonsystematic) review to determine the suggested sequence or combinations for the systemic treatment of mRCC. EVIDENCE ACQUISITION: PubMed and abstracts from main conferences up to December 2018 were reviewed to retrieve the current evidence for treatment of mRCC. Search terms included renal cell carcinoma, systemic therapy, targeted therapy (TT), and immunotherapy. EVIDENCE SYNTHESIS: Marked advances in the treatment of mRCC have been made with novel VEGFR tyrosine kinase inhibitors and multiple ICIs that have been included in the current treatment paradigm of mRCC. Remarkable advance has been made with the combination of double checkpoint blockade. The combination of ipilimumab and nivolumab compared with sunitinib has shown to increase the overall survival in the intermediate- and poor-risk patients based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. CONCLUSIONS: Double checkpoint blockade with ipilimumab and nivolumab has reported overall survival benefit in IMDC intermediate- and poor-risk patients, providing a durable response for a subset of patients. VEGF inhibitors remain the standard of care for favorable-risk patients in the first line. In the immediate future, more consolidated data on combination of VEGF-TT plus ICIs may show similar robust benefit with different safety profiles. PATIENT SUMMARY: Multiple drugs and sequences are now accepted as effective treatment for metastatic renal cell carcinoma (mRCC). Combination of immune checkpoint inhibitors has shown to increase the overall survival in treatment-naïve mRCC patients. Combinations of immunotherapy and antiangiogenics may be another option in the near future. Outcomes of the first line will determine the sequence, although the best sequence has yet to be defined.
引用
- de Velasco G, Bex A, Albiges L, et al. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2019. PMID: 31377308. doi:10.1016/j.euo.2019.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。